PDGFRA and central nervous system cancer: Hence, rat glioma 101.8 is potentially a quite reliable preclinical model to evaluate the anti-tumor efficacy of SOX2-, OLIG1/2-, and PDGFRA-targeting therapy approaches [25,32].